Role of Omalizumab in Chronic Idiopathic Urticaria

Speciality: Dermatlogy

Description:

A warm welcome to all the medical professionals in this interesting session on Role of Omalizumab in Chronic Idiopathic Urticaria
Omalizumab, a monoclonal antibody, has significantly impacted the treatment of chronic idiopathic urticaria (CIU), a condition characterized by persistent hives and itching without an identifiable cause. By targeting immunoglobulin E (IgE), Omalizumab helps reduce the allergic response that contributes to CIU symptoms, offering relief to patients who have not responded adequately to conventional therapies.
Omalizumab works by binding to IgE, preventing it from attaching to receptors on mast cells and basophils. This action inhibits the release of histamine and other inflammatory mediators that cause hives and itching in CIU. By reducing the levels of free IgE, Omalizumab effectively diminishes the severity and frequency of urticaria symptoms.
Patients treated with Omalizumab often experience significant reductions in the number of hives, itch severity, and overall disease activity. Many patients report substantial improvement in quality of life, as the treatment helps control the debilitating symptoms of CIU.
Therefore, get an overall knowledge of updated role of omalizumab in chronic idiopathic urticaria
 

See More Webinars @ Hidoc Webinars